Drug
Ft516
Ft516: highest development phase Phase 1, developed by Fate Therapeutics. 2 trial records tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Fate Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| FT516 NCT04023071 | Phase 1 | Acute Myelogenous Leukemia |
| FT516 NCT04551885 | Phase 1 | Solid Tumor, Adult |
Latest
No recent events.
Follow Ft516 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.